Articles Related to antiretroviral therapy
CCR5 Promoter SNP Genotype in HIV Seropositive Infants on Combination Antiretroviral Therapy in Uganda: Association with Virological Failure
According to the UNAIDS 2022 report, 52% of the HIV positive children between 0-14 years were able to access treatment and of these 68% attain viral suppression. CCR5 promoter genotype specifically single nucleotide polymorphisms have been linked to modulate patient virological status. However, the few studies that have studied the association in infants have utilized allele-specific PCR a genotypic method limited to detecting already known SNPs. By using Sanger sequencing, we explored the association taking into account novel mutations.
Introduction: The use of anti-retroviral drugs slows down disease progression in Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) and this has improved the quality of life and life expectancy of Persons Living with HIV/AIDS (PLWHA). However, optimum use of antiretroviral drugs (adherence) by PLWHA is the key to achieving viral load suppression and preventing drug resistance in them. Objective: This study determined the level of adherence to Anti-Retroviral Therapy (ART) among PLWHA in Ekiti State. Methodology: A cross-sectional study was conducted on 320 PLWHA in Ekiti State University Teaching Hospital, Ado-Ekiti and 300 PLWHA in Federal Teaching Hospital, Ido-Ekiti aged 18 years and above using ARV for at least six months prior to the study. Quantitative data were collected from the participants using a structured questionnaire while sixteen in-depth interviews were conducted among purposively selected PLWHA in both study centres to further elicit qualitative information on determinants of adherence. Quantitative data were analyzed with SPSS 22 using descriptive statistics while content analysis was used for qualitative data. Regression analysis was done to identify determinants of adherence at p value < 0.05. Results: About 60% of the PLWHA had high level of ART adherence while 18.9% had low adherence. Most of the respondents were female (66.0%), married (76.1%) and Christians (89.4%) and had post-secondary education (43.4%). Respondents’ age (X2=32.483), educational status (X2=2.473), marital status (X2=40.083), occupation (X2=57.951) and distance from the clinic (X2=13.181) significantly influenced the level of adherence. Patient factors such as forget timing of the medication, pill burden and feeling better, psychosocial factors like stigmatization, non-disclosure of status and depression; and healthcare factors such as long clinic waiting time and absence of support are some of the barriers to optimum ART adherence. Conclusion: Counseling on drug adherence and psycho-social support to PLWHA will further improve their level of adherence to medication.
An Introduction to the Approaches of Novel Drug Delivery Systems for Acquired Immune Deficiency Syndrome (AIDS)
The currently available anti HIV agents have several drawbacks such as short half life, low bioavailability, poor CNS penetration and retention, hepatic first pass metabolism, undesirable side effects and frequent dosing regimen.
The development of effective drug delivery approaches for the treatment of AIDS and HIV infection is a global challenge. The advent of multidrug, highly active antiretroviral therapy (HAART), have increased the life span of HIV-infected patients.
It is widely known that many problems in the mathematical biology can be modeled by the differential equations, and the corresponding systems are usually called as biological dynamic systems.
Acquired Immune Deficiency Syndrome (AIDS) is a spectrum of conditions caused by infection with the human immunodeficiency virus (HIV). They get it after being infected with the HIV virus. HIV (human immunodeficiency virus) is a retrovirus that primarily infects components of the immune system.
Accelerated aging and higher co-morbidity prevalence have increased non-antiretroviral (ARV) medications for HIV patients. We examined, over a 12 month period, non-ARV medication burden among HIV-positive patients 18-49 and ≥50 years using a comprehensive U.S. healthcare claims database in an age-and-gender matched analysis (1:3 matching ratio of cases to controls). Primary outcomes of interest included the median and mean number of unique non-ARV drug substances during the one month period with the highest number of prescriptions filled for each individual, and the mean number of unique classes of medication.